ArticleJournal of molecular histology2025
Synaptotagmin-like 5 is a potential biomarker and correlates with immune infiltrates in thyroid carcinoma.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SYTL5 drives malignant progression in differentiated thyroid carcinoma: unveiling its regulatory mechanisms.Frontiers in oncology · 2026Article
- Precision Thyroid Oncology: A Review of Multi-Omics Biomarkers and Spatiotemporal Technologies.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Thyroid carcinoma (TC) continues to show concerning rates of metastasis and recurrence, despite an overall favorable prognosis. This study aimed to investigate the characteristics and predictive value of synaptotagmin-like 5 (SYTL5) expression and its association with immune infiltration and potential effects on cell apoptosis and proliferation in TC. Messenger ribonucleic acid expression profiles from 45 TC samples and 37 normal samples in The Cancer Genome Atlas database were analysed. The differentially expressed gene SYTL5 was highly expressed in TC tissues and closely associated with the tumour-node-metastasis classification in TC. The receiver operating characteristic curve for predicting TC showed an area under the curve of 0.878. Immune cell expression significantly differed between SYTL5 low- and high-expression groups. Zinc-finger protein 384 (ZNF384) was predicted as the transcription factor of SYTL5 and was found to be underexpressed in TC tissues, showing a negative correlation with SYTL5. Molecular biology experiments demonstrated that SYTL5 expression was elevated in human TC cells and tissues, while SYTL5 knockdown promoted apoptosis and inhibited proliferation in vitro. Zinc-finger protein 384 was shown to bind to the promoter of SYTL5, and overexpression of SYTL5 reversed the effects of ZNF384 overexpression on TC cells. These findings indicate that SYTL5 acts as a potential oncogene in TC and may serve as a biomarker for TC diagnosis. Moreover, this study enhances our understanding of TC's underlying mechanisms and highlights SYTL5 as a promising target for immunotherapy.
Indexed as
Identifiers
40921909What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.